Nanobody Therapeutics Market Size, Share & Industry Analysis, By Molecule (Caplacizumab (Cablivi), Ozoralizumab (Nanozora), Envafolimab, and Others), By Nanobody Type (Bivalent, Trivalent, Fc-fused / Half-life Extended, and Others), By Disease Indication (Hematological / Blood Disorders, Rheumatoid Arthritis, Oncology, and Others) By Route of Administration (Intravenous, Subcutaneous, and Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Others), and Regional Forecast, 2026-2034

Last Updated: April 08, 2026 | Format: PDF | Report ID: FBI115882

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 19.53% from 2026-2034
Unit	Value (USD Million)
Segmentation	By Molecule, Nanobody Type, Disease Indication, Route of Administration, Distribution Channel, and Region
By Molecule	Caplacizumab (Cablivi) Ozoralizumab (Nanozora) Envafolimab Others
By Nanobody Type	Bivalent Trivalent Fc-fused / Half-life extended Others
By Disease Indication	Hematological / Blood Disorders Rheumatoid Arthritis Oncology Others
By Route of Administration	Intravenous Subcutaneous Others
By Distribution Channel	Hospital Pharmacies Specialty Pharmacies Others
By Region	North America (By Molecule, Nanobody Type, Disease Indication, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Molecule, Nanobody Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Molecule, Nanobody Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Rest of the World (By Molecule, Nanobody Type, Disease Indication, Route of Administration, and Distribution Channel)